Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1963
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1964 6
1965 2
1966 6
1967 5
1968 7
1969 5
1970 3
1971 6
1972 21
1973 6
1974 11
1975 7
1976 5
1977 11
1978 9
1979 10
1980 9
1981 7
1982 7
1983 8
1984 8
1985 12
1986 40
1987 38
1988 36
1989 63
1990 69
1991 85
1992 124
1993 93
1994 82
1995 87
1996 118
1997 102
1998 109
1999 95
2000 94
2001 97
2002 135
2003 122
2004 125
2005 131
2006 130
2007 173
2008 152
2009 170
2010 189
2011 204
2012 232
2013 210
2014 179
2015 201
2016 181
2017 219
2018 255
2019 227
2020 229
2021 228
2022 191
2023 238
2024 226
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

5,418 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiology and Pathogenesis of Myelodysplastic Syndrome.
Rotter LK, Shimony S, Ling K, Chen E, Shallis RM, Zeidan AM, Stahl M. Rotter LK, et al. Cancer J. 2023 May-Jun 01;29(3):111-121. doi: 10.1097/PPO.0000000000000665. Cancer J. 2023. PMID: 37195766 Review.
Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. ...
Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a
Myelodysplastic Syndrome Updated.
Hasserjian RP. Hasserjian RP. Pathobiology. 2019;86(1):7-13. doi: 10.1159/000489702. Epub 2018 Jul 24. Pathobiology. 2019. PMID: 30041243 Review.
This review highlights the main changes in the revised 2016 WHO Classification of Myeloid Neoplasms (published in 2017) that impact the diagnosis and management of patients with myelodysplastic syndrome (MDS). The revision was based on data accumulated since the 200 …
This review highlights the main changes in the revised 2016 WHO Classification of Myeloid Neoplasms (published in 2017) that impact the diag …
Childhood Myelodysplastic Syndrome.
Chisholm KM, Bohling SD. Chisholm KM, et al. Clin Lab Med. 2023 Dec;43(4):639-655. doi: 10.1016/j.cll.2023.06.005. Epub 2023 Aug 7. Clin Lab Med. 2023. PMID: 37865508 Review.
Myelodysplastic syndrome (MDS) in children is rare, accounting for < 5% of all childhood hematologic malignancies. ...
Myelodysplastic syndrome (MDS) in children is rare, accounting for < 5% of all childhood hematologic malignancies. ...
The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M, Weinberg OK, Niemeyer CM, Shimamura A, Calvo KR. Rudelius M, et al. Virchows Arch. 2023 Jan;482(1):113-130. doi: 10.1007/s00428-022-03447-9. Epub 2022 Nov 29. Virchows Arch. 2023. PMID: 36445482 Review.
Updating the classification of hematologic neoplasia with germline predisposition, pediatric myelodysplastic syndrome (MDS), and juvenile myelomonocytic leukemia (JMML) is critical for diagnosis, therapy, research, and clinical trials. ...We also detail advances in …
Updating the classification of hematologic neoplasia with germline predisposition, pediatric myelodysplastic syndrome (MDS), a …
Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
Lee P, Yim R, Yung Y, Chu HT, Yip PK, Gill H. Lee P, et al. Int J Mol Sci. 2021 Sep 23;22(19):10232. doi: 10.3390/ijms221910232. Int J Mol Sci. 2021. PMID: 34638574 Free PMC article. Review.
Myelodysplastic syndrome (MDS) is a heterogeneous, clonal hematological disorder characterized by ineffective hematopoiesis, cytopenia, morphologic dysplasia, and predisposition to acute myeloid leukemia (AML). ...
Myelodysplastic syndrome (MDS) is a heterogeneous, clonal hematological disorder characterized by ineffective hematopoiesis, c
Pediatric Myelodysplastic Syndromes.
Patel SS. Patel SS. Clin Lab Med. 2021 Sep;41(3):517-528. doi: 10.1016/j.cll.2021.03.015. Epub 2021 Jun 24. Clin Lab Med. 2021. PMID: 34304779 Review.
Pediatric myelodysplastic syndromes (MDS) comprise less than 5% of childhood malignancies. Approximately 30% to 45% of pediatric MDS cases are associated with an underlying genetic predisposition syndrome. ...
Pediatric myelodysplastic syndromes (MDS) comprise less than 5% of childhood malignancies. Approximately 30% to 45% of pediatr …
The Molecular Pathology of Myelodysplastic Syndrome.
Haferlach T. Haferlach T. Pathobiology. 2019;86(1):24-29. doi: 10.1159/000488712. Epub 2018 May 23. Pathobiology. 2019. PMID: 29791902 Review.
The diagnosis and classification of myelodysplastic syndromes (MDS) are based on cytomorphology and cytogenetics (WHO classification). ...
The diagnosis and classification of myelodysplastic syndromes (MDS) are based on cytomorphology and cytogenetics (WHO classifi …
New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A, Bravo GM. Bazinet A, et al. Curr Treat Options Oncol. 2022 May;23(5):668-687. doi: 10.1007/s11864-022-00965-1. Epub 2022 Mar 23. Curr Treat Options Oncol. 2022. PMID: 35320468 Review.
The treatment of myelodysplastic syndromes (MDS) begins with risk stratification using a validated tool such as the International Prognostic Scoring System (IPSS) or its revised version (IPSS-R). ...
The treatment of myelodysplastic syndromes (MDS) begins with risk stratification using a validated tool such as the Internatio …
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines.
DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE. DeFilipp Z, et al. Transplant Cell Ther. 2023 Feb;29(2):71-81. doi: 10.1016/j.jtct.2022.11.014. Epub 2022 Nov 25. Transplant Cell Ther. 2023. PMID: 36436780 Free article. Review.
The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated in the context of the evidence. ...
The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic cell transplantation (HCT). Here this …
Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.
Jain AG, Zhang L, Bennett JM, Komrokji R. Jain AG, et al. Ann Lab Med. 2022 May 1;42(3):299-305. doi: 10.3343/alm.2022.42.3.299. Ann Lab Med. 2022. PMID: 34907099 Free PMC article. Review.
Myelodysplastic syndrome (MDS) is a diverse hematological malignancy with a wide spectrum of presentations and implications. ...
Myelodysplastic syndrome (MDS) is a diverse hematological malignancy with a wide spectrum of presentations and implications. .
5,418 results